ULTRAGENYX PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.37 USD | -2.33% |
|
-9.85% | -11.40% |
Presenter SpeechYigal Nochomovitz (Analysts)Good morning, everyone. My name is Yigal Nochomovi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
42.37
USD
Average target price
90.05
USD
Spread / Average Target
+112.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.40% | 3.57B | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi's 17th Annual BioPharma Conference, Sep-07-2022 11
